A study from the Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark; and Hypoxia and Metastasis Team, Cancer Research UK Tumour Cell Signalling Unit, The Institute of Cancer Research, London SW3 6JB, UK shows that “The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.” This study was published in the 27 May 2015 issue of the journal “Nature” [the number 1 journal in General Science with an I.F of >42] by Prof. Janine T. Erler, Cox and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for metastatic breast cancer: Tumor suppressor Grhl3 blocks bone metastasis of mammary cancer via down regulation of its target gene
Given that: (1) cancer causes the highest economic loss compared to all the known causes of death worldwide; (2) in 2008, mammary cancer has caused more than 400000 deaths; (3) mammary cancer is the most common invasive cancer in women; and (4) in 2008, breast cancer has caused economic loss of 88 billion US dollars worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression of breast cancer.
Breast cancer is the most common women cancer. It metastasizes to bone in ~80% of the cases. However, the mechanistic basis of which remains largely unclear. Erler’s research team has recently shown that increased expression of lysyl oxidase (LOX) in breast cancer cells results in osteolytic bone lesion, suggesting that down regulation of LOX expression may result in inhibition of bone metastasis of breast cancer.
PAPD5 has been shown to function as a tumor suppressor. This study suggests, for the first time, that Tumor suppressor Grhl3, by suppressing the expression of its target gene, it may decrease the expression of lysyl oxidase (LOX). Thereby, it may inhibit metastasis of mammary cancer. Thus, pharmacological formulations encompassing “Grhl3 activators” may be used to treat metastatic breast cancer.
Undisclosed information: How Tumor suppressor Grhl3 suppresses the expression of lysyl oxidase (LOX).
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for metastatic breast cancer: Tumor suppressor Grhl3 blocks bone metastasis of mammary cancer via down regulation of its target gene, 13/June/2015, 11.13 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
* Research cooperation